LungLife
AI, Inc.
(the "Company"
or "LungLife")
LungLife to
present at US National Cancer Institute's Early Detection Research
Network Meeting
LungLife AI (AIM:
LLAI), a developer of clinical diagnostic solutions for the early
detection of lung cancer, announces it has been invited to present
at the National Cancer Institute's ("NCI") Early Detection Research
Network ("EDRN") meeting in Tempe, Arizona on 17 April
2024.
The EDRN is a
division of the United States NCI, the federal government's
principal agency for cancer research and training, which
works collaboratively
amongst its members to bring new diagnostic biomarkers to clinical
use.
In October 2022, LungLife was selected to participate in
the Lung Cancer Biomarker Development Laboratory of the EDRN,
combining LungLB® with imaging to assist early detection research,
as well as validate combined test performance in patients with
indeterminate lung nodules.
In this
meeting, LungLife will present the LungLB® test, including results
from the validation study and information on the Early Access
Program, and describe its role in the ongoing EDRN study for
indeterminate lung nodules to a group of over 300 investigators
from the NCI, academic institutions and industry focused on early
cancer detection.
Paul Pagano, CEO of LungLife AI,
said "We are excited that through our
ongoing EDRN partnership we have the opportunity to present at this
meeting to collaborators and potential end users of
LungLB®.
"The work of the EDRN closely aligns with
LungLife's mission to drive the early detection of lung cancer and
will provide further clinical evidence for the LungLB® technology
as well as widen awareness of our technology with leading US
investigators and diagnostics industry partners."
For further information please
contact:
|
LungLife AI, Inc.
|
www.lunglifeai.com
|
|
Paul
Pagano, CEO
|
Via
Walbrook PR
|
|
David
Anderson, CFO
|
|
|
|
|
|
Investec Bank plc (Nominated Adviser
& Joint Broker)
|
Tel: +44 (0)20 7597 5970
|
|
Virginia Bull /
Cameron MacRitchie / Lydia Zychowska
|
|
|
|
|
|
Goodbody (Joint
Broker)
Tom
Nicholson / Cameron Duncan
|
Tel: +44 (0) 20 3841 6208
|
|
Walbrook
PR Limited
|
Tel: +44 (0)20 7933 8780
or LungLifeAI@walbrookpr.com
|
|
Paul
McManus / Alice Woodings / Phillip Marriage
|
Mob: 07980 541 893 / 07407 804 654 / 07867
984 082
|
About
LungLife
LungLife AI is a developer of clinical
diagnostic solutions designed to make a significant impact in the
early detection of lung cancer, the deadliest cancer
globally. Using a
minimally invasive blood draw, the Company's LungLB® test is
designed to deliver additional information to clinicians who are
evaluating indeterminate lung nodules. For more information visit
www.lunglifeai.com
About
Lung Cancer
Lung
cancer is the most fatal form of cancer worldwide and early
detection is critical to achieve better outcomes. Early detection
involves the evaluation of indeterminate lung nodules, of which
there are over 1.5M identified by CT scan each year in the United
States alone. Evaluation often involves significant unnecessary
invasive procedures such as biopsy for patients with benign nodules
and long delays in potentially curative treatment for patients with
cancerous nodules that are selected for monitoring via non-invasive
imaging. LungLB® is intended to help with earlier diagnosis in the
evaluation process.